Literature DB >> 29862493

Characteristics of depressive and bipolar disorder patients with mixed features.

L Tondo1,2,3, G H Vázquez1,4, M Pinna3, P A Vaccotto5, R J Baldessarini1,2.   

Abstract

OBJECTIVE: To assess differences between subjects with vs. without mixed features in major affective disorders.
METHODS: In 3099 out-patient subjects with DSM-5 major depressive disorder (MDD, n = 1921) or bipolar disorders (BD, n = 1178), we compared those with (Mx) vs. without (Non-Mx) mixed features (agitated-irritable depression or dysphoric [hypo]mania) in an index episode.
RESULTS: Prevalence of Mx averaged 21.9% [CI: 20.5-23.4] overall, ranking: BD-II > BD-I > MDD, and in BD depression ≥ [hypo]mania > MDD. Mx subjects were significantly more likely than Non-Mx cases to (i) have other mixed episodes, (ii) have higher irritable and agitated ratings, (iii) have more substance abuse, (iv) switch into mixed episodes, (v) have more suicide attempts and higher suicidal ratings, (vi) change diagnosis from depression to BD, (vii) have higher hypomania scores when depressed or depression scores when [hypo]manic, (viii) be unmarried or separated with fewer children and siblings, (ix) be diagnosed more with BD than MDD, (x) be unemployed, (xi) have BD, suicide and divorce among first-degree relatives, (xii) be female, (xiii) be younger at illness-onset. Both BD and MDD Mx subjects also received antidepressants less, but antipsychotics and mood-stabilizers more, alone and in combination with antidepressants.
CONCLUSIONS: Mood disorder subjects with agitated-irritable depression or dysphoric [hypo]mania differed from those without such mixed features, including having a less favorable clinical course and repeated mixed episodes. They may represent a distinct and prevalent, syndromal clinical subtype with prognostic and therapeutic significance.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bipolar disorder; depression; hypomania; major depressive disorder; mania; mixed features

Mesh:

Substances:

Year:  2018        PMID: 29862493     DOI: 10.1111/acps.12911

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  6 in total

1.  Distribution of agitation and related symptoms among hospitalized patients using a scalable natural language processing method.

Authors:  Kamber L Hart; Amelia M Pellegrini; Brent P Forester; Sabina Berretta; Shawn N Murphy; Roy H Perlis; Thomas H McCoy
Journal:  Gen Hosp Psychiatry       Date:  2020-11-10       Impact factor: 3.238

Review 2.  Strategies and foundations for scientific discovery in longitudinal studies of bipolar disorder.

Authors:  Melvin G McInnis; Ole A Andreassen; Ana C Andreazza; Uri Alon; Michael Berk; Teri Brister; Katherine E Burdick; Donghong Cui; Mark Frye; Marion Leboyer; Philip B Mitchell; Kathleen Merikangas; Andrew A Nierenberg; John I Nurnberger; Daniel Pham; Eduard Vieta; Lakshmi N Yatham; Allan H Young
Journal:  Bipolar Disord       Date:  2022-03-18       Impact factor: 5.345

3.  Comparison of the Emotion Regulation and Temperament Characteristics Between Depressive Patients With and Without Mixed Features.

Authors:  Halil İbrahim Taş; Kürşat Altinbaş
Journal:  Noro Psikiyatr Ars       Date:  2019-09-12       Impact factor: 1.339

Review 4.  Bipolar depression: a major unsolved challenge.

Authors:  Ross J Baldessarini; Gustavo H Vázquez; Leonardo Tondo
Journal:  Int J Bipolar Disord       Date:  2020-01-06

5.  Clinical course and need for hospital admission after lithium discontinuation in patients with bipolar disorder type I or II: mirror-image study based on the LiSIE retrospective cohort.

Authors:  Louise Öhlund; Michael Ott; Malin Bergqvist; Sofia Oja; Robert Lundqvist; Mikael Sandlund; Ellinor Salander Renberg; Ursula Werneke
Journal:  BJPsych Open       Date:  2019-11-22

6.  Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium.

Authors:  Gustavo H Vázquez; Anees Bahji; Juan Undurraga; Leonardo Tondo; Ross J Baldessarini
Journal:  J Psychopharmacol       Date:  2021-07-09       Impact factor: 4.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.